vs
Columbia Financial, Inc.（CLBK）与RECURSION PHARMACEUTICALS, INC.（RXRX）财务数据对比。点击上方公司名可切换其他公司
Columbia Financial, Inc.的季度营收约是RECURSION PHARMACEUTICALS, INC.的1.9倍（$68.8M vs $35.5M），Columbia Financial, Inc.净利率更高（22.8% vs -304.2%，领先327.1%），RECURSION PHARMACEUTICALS, INC.同比增速更快（681.7% vs 29.7%），Columbia Financial, Inc.自由现金流更多（$58.6M vs $-47.3M），过去两年RECURSION PHARMACEUTICALS, INC.的营收复合增速更高（60.5% vs 17.7%）
哥伦比亚金融公司（CLBK）是一家美国多元化金融服务及银行控股企业，提供财富管理、资产管理、保险、年金、遗产规划在内的全方位金融规划产品与服务，满足客户不同阶段的财务规划需求。
Recursion Pharmaceuticals是一家临床阶段生物技术企业，依托人工智能技术和高通量生物实验体系，开发针对罕见病、肿瘤、炎症性疾病等领域未满足医疗需求的创新疗法，核心市场覆盖北美，与全球多家生物制药企业合作推进在研管线落地。
CLBK vs RXRX — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $68.8M | $35.5M |
| 净利润 | $15.7M | $-108.1M |
| 毛利率 | — | 59.8% |
| 营业利润率 | 28.6% | -304.8% |
| 净利率 | 22.8% | -304.2% |
| 营收同比 | 29.7% | 681.7% |
| 净利润同比 | 173.9% | 39.6% |
| 每股收益（稀释后） | $0.15 | $-0.17 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $68.8M | $35.5M | ||
| Q3 25 | $67.3M | $5.2M | ||
| Q2 25 | $63.9M | $19.2M | ||
| Q1 25 | $58.8M | $14.7M | ||
| Q4 24 | $46.4M | $4.5M | ||
| Q3 24 | $54.3M | $26.1M | ||
| Q2 24 | $53.3M | $14.4M | ||
| Q1 24 | $49.7M | $13.8M |
| Q4 25 | $15.7M | $-108.1M | ||
| Q3 25 | $14.9M | $-162.3M | ||
| Q2 25 | $12.3M | $-171.9M | ||
| Q1 25 | $8.9M | $-202.5M | ||
| Q4 24 | $-21.2M | $-178.9M | ||
| Q3 24 | $6.2M | $-95.8M | ||
| Q2 24 | $4.5M | $-97.5M | ||
| Q1 24 | $-1.2M | $-91.4M |
| Q4 25 | — | 59.8% | ||
| Q3 25 | — | -183.8% | ||
| Q2 25 | — | -4.9% | ||
| Q1 25 | — | -48.0% | ||
| Q4 24 | — | -181.4% | ||
| Q3 24 | — | 53.7% | ||
| Q2 24 | — | 36.2% | ||
| Q1 24 | — | 19.1% |
| Q4 25 | 28.6% | -304.8% | ||
| Q3 25 | 29.5% | -3327.6% | ||
| Q2 25 | 25.8% | -916.8% | ||
| Q1 25 | 20.4% | -1297.9% | ||
| Q4 24 | -57.6% | -4042.4% | ||
| Q3 24 | 13.5% | -377.1% | ||
| Q2 24 | 9.0% | -697.4% | ||
| Q1 24 | -2.6% | -698.4% |
| Q4 25 | 22.8% | -304.2% | ||
| Q3 25 | 22.1% | -3135.3% | ||
| Q2 25 | 19.3% | -894.2% | ||
| Q1 25 | 15.1% | -1373.3% | ||
| Q4 24 | -45.7% | -3935.5% | ||
| Q3 24 | 11.4% | -367.5% | ||
| Q2 24 | 8.5% | -676.6% | ||
| Q1 24 | -2.3% | -662.4% |
| Q4 25 | $0.15 | $-0.17 | ||
| Q3 25 | $0.15 | $-0.36 | ||
| Q2 25 | $0.12 | $-0.41 | ||
| Q1 25 | $0.09 | $-0.50 | ||
| Q4 24 | $-0.20 | $-0.56 | ||
| Q3 24 | $0.06 | $-0.34 | ||
| Q2 24 | $0.04 | $-0.40 | ||
| Q1 24 | $-0.01 | $-0.39 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $340.8M | $743.3M |
| 总债务越低越好 | $1.2B | $9.6M |
| 股东权益账面价值 | $1.2B | $1.1B |
| 总资产 | $11.0B | $1.5B |
| 负债/权益比越低杠杆越低 | 1.02× | 0.01× |
8季度趋势，按日历期对齐
| Q4 25 | $340.8M | $743.3M | ||
| Q3 25 | $253.4M | $659.8M | ||
| Q2 25 | $248.2M | $525.1M | ||
| Q1 25 | $256.1M | $500.5M | ||
| Q4 24 | $289.2M | $594.4M | ||
| Q3 24 | $283.5M | $427.6M | ||
| Q2 24 | $391.1M | $474.3M | ||
| Q1 24 | $373.5M | $296.3M |
| Q4 25 | $1.2B | $9.6M | ||
| Q3 25 | $1.3B | $11.9M | ||
| Q2 25 | $1.3B | $14.2M | ||
| Q1 25 | $1.1B | $16.4M | ||
| Q4 24 | $1.1B | $19.0M | ||
| Q3 24 | $1.4B | $20.5M | ||
| Q2 24 | $1.7B | $22.9M | ||
| Q1 24 | $1.5B | — |
| Q4 25 | $1.2B | $1.1B | ||
| Q3 25 | $1.1B | $1.0B | ||
| Q2 25 | $1.1B | $919.1M | ||
| Q1 25 | $1.1B | $933.9M | ||
| Q4 24 | $1.1B | $1.0B | ||
| Q3 24 | $1.1B | $524.6M | ||
| Q2 24 | $1.0B | $584.4M | ||
| Q1 24 | $1.0B | $401.2M |
| Q4 25 | $11.0B | $1.5B | ||
| Q3 25 | $10.9B | $1.4B | ||
| Q2 25 | $10.7B | $1.3B | ||
| Q1 25 | $10.6B | $1.3B | ||
| Q4 24 | $10.5B | $1.4B | ||
| Q3 24 | $10.7B | $726.5M | ||
| Q2 24 | $10.8B | $775.9M | ||
| Q1 24 | $10.6B | $557.8M |
| Q4 25 | 1.02× | 0.01× | ||
| Q3 25 | 1.11× | 0.01× | ||
| Q2 25 | 1.14× | 0.02× | ||
| Q1 25 | 1.01× | 0.02× | ||
| Q4 24 | 1.00× | 0.02× | ||
| Q3 24 | 1.32× | 0.04× | ||
| Q2 24 | 1.61× | 0.04× | ||
| Q1 24 | 1.47× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $68.4M | $-46.1M |
| 自由现金流经营现金流 - 资本支出 | $58.6M | $-47.3M |
| 自由现金流率自由现金流/营收 | 85.1% | -133.1% |
| 资本支出强度资本支出/营收 | 14.3% | 3.5% |
| 现金转化率经营现金流/净利润 | 4.36× | — |
| 过去12个月自由现金流最近4个季度 | $95.1M | $-378.3M |
8季度趋势，按日历期对齐
| Q4 25 | $68.4M | $-46.1M | ||
| Q3 25 | $31.0M | $-117.4M | ||
| Q2 25 | $14.6M | $-76.4M | ||
| Q1 25 | $-1.6M | $-132.0M | ||
| Q4 24 | $33.3M | $-115.4M | ||
| Q3 24 | $-28.3M | $-59.2M | ||
| Q2 24 | $18.6M | $-82.2M | ||
| Q1 24 | $14.1M | $-102.3M |
| Q4 25 | $58.6M | $-47.3M | ||
| Q3 25 | $28.1M | $-117.6M | ||
| Q2 25 | $12.9M | $-79.6M | ||
| Q1 25 | $-4.5M | $-133.8M | ||
| Q4 24 | $25.9M | $-116.7M | ||
| Q3 24 | $-31.1M | $-63.8M | ||
| Q2 24 | $17.2M | $-83.4M | ||
| Q1 24 | $12.5M | $-109.0M |
| Q4 25 | 85.1% | -133.1% | ||
| Q3 25 | 41.8% | -2272.5% | ||
| Q2 25 | 20.2% | -413.9% | ||
| Q1 25 | -7.6% | -907.4% | ||
| Q4 24 | 55.7% | -2567.7% | ||
| Q3 24 | -57.3% | -244.6% | ||
| Q2 24 | 32.3% | -578.5% | ||
| Q1 24 | 25.1% | -789.9% |
| Q4 25 | 14.3% | 3.5% | ||
| Q3 25 | 4.2% | 4.7% | ||
| Q2 25 | 2.7% | 16.4% | ||
| Q1 25 | 4.9% | 12.4% | ||
| Q4 24 | 16.0% | 28.6% | ||
| Q3 24 | 5.1% | 17.5% | ||
| Q2 24 | 2.6% | 8.2% | ||
| Q1 24 | 3.4% | 48.2% |
| Q4 25 | 4.36× | — | ||
| Q3 25 | 2.08× | — | ||
| Q2 25 | 1.19× | — | ||
| Q1 25 | -0.18× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -4.57× | — | ||
| Q2 24 | 4.09× | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
